Prediction of Survival of Metastatic Prostate Cancer Based on Early Serial Measurements of Prostate Specific Antigen and Alkaline Phosphatase

Journal of Urology

Volumn 179, Issue 1, 2008, Pages 117-123

  Robinson, David ^a   Sandblom, Gabriel ^b   Johansson, Robert ^c   Garmo, Hans ^d   Stattin, Pär ^c   Mommsen, Sören ^f   Varenhorst, Eberhard ^e  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f RANDERS REGIONAL HOSPITAL   (Denmark)

Author keywords

alkaline phosphatase; prostate specific antigen; prostatic neoplasms; survival

Indexed keywords

ALKALINE PHOSPHATASE; ANDROGEN; ESTROGEN; FLUTAMIDE; POLYESTRADIOL PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORCHIECTOMY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; HUMANS; MALE; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 36749096941     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.08.132     Document Type: Article

References (17)

1. Aus G., Robinson D., Rosell J., Sandblom G., and Varenhorst E. Survival in prostate carcinoma-outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 103 (2005) 943
2. Lucas A., and Petrylak D.P. The case for early chemotherapy for the treatment of metastatic disease. J Urol 176 (2006) S72
3. Ernst D.S., Hanson J., and Venner P.M. Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J Urol 146 (1991) 372
4. Reynard J.M., Peters T.J., and Gillatt D. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer-a multivariable analysis of prostate cancer mortality. Br J Urol 75 (1995) 507
5. Furuya Y., Akakura K., Tobe T., Ichikawa T., Igarashi T., and Ito H. Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment. Int Urol Nephrol 32 (2001) 659
6. Kwak C., Jeong S.J., Park M.S., Lee E., and Lee S.E. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 168 (2002) 995
7. Sim H.G., Lau W.K., and Cheng C.W. Predictors of androgen independence in metastatic prostate cancer. BJU Int 93 (2004) 1221
8. Pelger R.C., Lycklama A.N.G.A., Zwinderman A.H., Papapoulos S.E., and Hamdy N.A. The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma. J Urol 156 (1996) 122
9. Smith Jr. J.A., Lange P.H., Janknegt R.A., Abbou C.C., and deGery A. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol 157 (1997) 1329
10. Nakashima J., Ozu C., Nishiyama T., Oya M., Ohigashi T., Asakura H., et al. Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy. Urology 56 (2000) 843
11. Hedlund P.O., and Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 55 (2000) 328
12. Vollmer R.T., Egawa S., Kuwao S., and Baba S. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. Cancer 94 (2002) 1692
13. Cox D.R. Regression models and life-tables. J R Stat Soc B 34 (1972) 187
14. Heagerty P.J., Lumley T., and Pepe M.S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56 (2000) 337
15. Kalbfleisch D.L., and Prentice R.L. The statistical analysis of failure time data (2002), John Wiley, New York 252
16. Fall K., Garmo H., Andrén O., Bill-Axelsson A., Adolfsson J., Adami H.O., et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99 (2007) 526
17. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502